Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide

Ryan T. Nitta, Sara Bolin, Emily Luo, David E. Solow-Codero, Peyman Samghabadi, Teresa Purzner, Parvir S. Aujla, Ginikachi Nwagbo, Yoon-Jae Cho, Gordon Li

Research output: Contribution to journalArticle

Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced β-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

temozolomide
Casein Kinase II
Medulloblastoma
O(6)-Methylguanine-DNA Methyltransferase
Growth
Cell Survival
Carcinogenesis
Apoptosis
Catenins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Nitta, R. T., Bolin, S., Luo, E., Solow-Codero, D. E., Samghabadi, P., Purzner, T., ... Li, G. (Accepted/In press). Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. Oncogene. https://doi.org/10.1038/s41388-019-0927-y

Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. / Nitta, Ryan T.; Bolin, Sara; Luo, Emily; Solow-Codero, David E.; Samghabadi, Peyman; Purzner, Teresa; Aujla, Parvir S.; Nwagbo, Ginikachi; Cho, Yoon-Jae; Li, Gordon.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Nitta, RT, Bolin, S, Luo, E, Solow-Codero, DE, Samghabadi, P, Purzner, T, Aujla, PS, Nwagbo, G, Cho, Y-J & Li, G 2019, 'Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide', Oncogene. https://doi.org/10.1038/s41388-019-0927-y
Nitta RT, Bolin S, Luo E, Solow-Codero DE, Samghabadi P, Purzner T et al. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. Oncogene. 2019 Jan 1. https://doi.org/10.1038/s41388-019-0927-y
Nitta, Ryan T. ; Bolin, Sara ; Luo, Emily ; Solow-Codero, David E. ; Samghabadi, Peyman ; Purzner, Teresa ; Aujla, Parvir S. ; Nwagbo, Ginikachi ; Cho, Yoon-Jae ; Li, Gordon. / Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide. In: Oncogene. 2019.
@article{d9b3f11743e94a81985590a07d0526b1,
title = "Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide",
abstract = "Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced β-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.",
author = "Nitta, {Ryan T.} and Sara Bolin and Emily Luo and Solow-Codero, {David E.} and Peyman Samghabadi and Teresa Purzner and Aujla, {Parvir S.} and Ginikachi Nwagbo and Yoon-Jae Cho and Gordon Li",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0927-y",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide

AU - Nitta, Ryan T.

AU - Bolin, Sara

AU - Luo, Emily

AU - Solow-Codero, David E.

AU - Samghabadi, Peyman

AU - Purzner, Teresa

AU - Aujla, Parvir S.

AU - Nwagbo, Ginikachi

AU - Cho, Yoon-Jae

AU - Li, Gordon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced β-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.

AB - Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Since surviving patients experience severe neurocognitive disabilities, better and more effective treatments are needed to enhance their quality of life. Casein kinase 2 (CK2) is known to regulate cell growth and survival in multiple cancers; however, the role of CK2 in MB is currently being studied. In this study, we verified the importance of CK2 in MB tumorigenesis and discovered that inhibition of CK2 using the small molecule inhibitor, CX-4945, can sensitize MB cells to a well-known and tolerated chemotherapeutic, temozolomide (TMZ). To study the role of CK2 in MB we modulated CK2 expression in multiple MB cells. Exogenous expression of CK2 enhanced cell growth and tumor growth in mice, while depletion or inhibition of CK2 expression decreased MB tumorigenesis. Treatment with CX-4945 reduced MB growth and increased apoptosis. We conducted a high-throughput screen where 4000 small molecule compounds were analyzed to identify compounds that increased the anti-tumorigenic properties of CX-4945. TMZ was found to work synergistically with CX-4945 to decrease cell survival and increase apoptosis in MB cells. O-6-methylguanine-DNA methyltransferase (MGMT) activity is directly correlated to TMZ sensitivity. We found that loss of CK2 activity reduced β-catenin expression, a known MGMT regulator, which in turn led to a decrease in MGMT expression and an increased sensitivity to TMZ. Our findings show that CK2 is important for MB maintenance and that treatment with CX-4945 can sensitize MB cells to TMZ treatment.

UR - http://www.scopus.com/inward/record.url?scp=85070840877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070840877&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0927-y

DO - 10.1038/s41388-019-0927-y

M3 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -